drugset / Trial / NCT01116141

A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)

NCT01116141

Phase 2 Completed 250 enrolled Chelsea Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if CH-4051 is a safe and effective treatment for rheumatoid arthritis.

Timeline

Start
2010-09
Primary completion
2012-04
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CH-1504 L-ISOMER Small molecule 0.3 mg
Subject CH-1504 L-ISOMER Small molecule 1 mg
Subject CH-1504 L-ISOMER Small molecule 3 mg
Comparator Methotrexate Small molecule 20 mg
Background folic acid Other / unclassified 1 mg Oral

Indications